Clinical trial NCT00998270: Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma
Official title: A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation Compare With Allogeneic Bone Marrow Transplantation in Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Multiple Myeloma
Keywords: MM
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
First posted: 2009-10-20
Enrollment: 185
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A prospective, randomized trial of autologous bone marrow transplantation compared with allogeneic bone marrow transplantation in multiple myeloma.


Eligibility criteria: Inclusion Criteria:

* Age at diagnosis equal or under 55 year
* Meeting the Durie and Salmon criteria for initial diagnosis of MM
* Stage II or III MM at diagnosis or anytime thereafter
* Symptomatic MM requiring treatment at diagnosis or anytime thereafter
* If receiving chemotherapy-based mobilization regimens, must be able to receive high-dose melphalan between 2 and 8 weeks after the initiation of mobilization therapy whether delivered at the transplant center or at a referring center
* Adequate organ function as measured by:

  * Cardiac: Left ventricular ejection fraction at rest greater than 40%
  * Hepatic: Bilirubin less than 2 times the upper limit of normal and ALT and AST less than 3 times the upper limit of normal
  * Renal: Creatinine clearance greater than 40 ml/min (measured or calculated/estimated)
  * Pulmonary: DLCO, FEV1, and FVC greater than 50% of predicted value (corrected for hemoglobin), or O2 saturation greater than 92% of room air
* An adequate autologous graft defined as a cryopreserved PBSC graft containing at least 4.0 x 10\^6 CD34+ cells/kg patient weight; if prior to enrollment it is known that a patient will be on the auto-allo arm (i.e., a consenting, eligible HLA-matched sibling donor is available), the required autograft must contain at least 2.0 x 10\^6 CD34+ cells/kg patient weight; the graft may not be CD34+ selected or otherwise manipulated to remove tumor or other cells; the graft can be collected at the transplanting institution or by a referring center; for patients without an HLA-matched sibling donor, the autograft must be stored so that there are two products each containing at least 2 x 10\^6 CD34+ cells/kg patient weight

Exclusion Criteria:

* Never advanced beyond Stage I MM since diagnosis
* Non-secretory MM (absence of a monoclonal protein \[M protein\] in serum as measured by electrophoresis and immunofixation and the absence of Bence Jones protein in the urine defined by use of conventional electrophoresis and immunofixation techniques)
* Plasma cell leukemia
* Karnofsky performance score less than 70%, unless approved by the Medical Monitor or one of the Protocol Chairs
* Uncontrolled hypertension
* Uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms)
* Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ; cancer treated with curative intent less than 5 years previously will not be allowed unless approved by the Medical Monitor or one of the Protocol Chairs; cancer treated with curative intent more than 5 years previously will be allowed
* Pregnant or breastfeeding
* Seropositive for the human immunodeficiency virus (HIV)
* Unwilling to use contraceptive techniques during and for 12 months following treatment
* Prior allograft or prior autograft
* Received mid-intensity melphalan (more than 50 mg IV) as part of prior therapy
* Prior organ transplant requiring immunosuppressive therapy

Primary outcomes:
measure: Overall Survival and Progressive Free Survival in both two arms
timeFrame: 1 year
Secondary outcomes:
measure: Overall Survival and Progressive Free Survival in both two arms
timeFrame: 3 year
measure: Treatment Related Mortality (TRM) in both two arms
timeFrame: 3 year
measure: Acute and Chronic GVHD in Allogeneic arm
timeFrame: 3 year
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Hematology-Oncology & SCT Research Center
Study officials:
affiliation: Hematology-Oncology and SCT Research Center
name: Ardeshir Ghavamzadeh, MD
role: PRINCIPAL_INVESTIGATOR
References: